InterVene’s Recana Thrombectomy System Studied for Venous ISR and RVO

October 13, 2026—Results from a prospective, multicenter study evaluated the Recana thrombectomy catheter system (InterVene, Inc.) for the treatment of venous in-stent restenosis (ISR) and residual vein obstruction (RVO). The study showed restoration of patency in 96.2% of target limbs after mechanical thrombectomy with the Recana system.

The findings were presented by Stephen Black, MD, at The VEINS conference held by the VIVA Foundation.

According to the VIVA Foundation’s summary of the presentation, the study evaluated the safety and effectiveness of the Recana integrated mechanical thrombectomy system for debulking chronic venous obstructions and occlusions in stented and nonstented venous segments.

The prospective analysis included patients aged ≥ 18 years with symptomatic chronic venous disease characterized by edema (CEAP class C3 or greater) or pain. Eligible patients had flow-limiting venous inflow or outflow obstruction > 50% in target vessels, including the inferior vena cava/common iliac confluence, femoral and popliteal veins, and inflow segments.

The primary effectiveness endpoint was achievement of an effective diameter ≥ 50% at procedure completion, as assessed by intravascular ultrasound. An independent data monitoring committee provided trial oversight. All interventions were completed in a single session under general anesthesia.

The investigators reported the following postprocedural findings:

• 96.2% of target limbs achieved patency.
• Mean lumen area increased from 12.5 to 92.7 mm² per segment, representing an approximately 7.4-fold increase
• Mean procedure time was 107 minutes.
• Mean postprocedural hospital length of stay was 1.4 days.

According to the investigators, mechanical thrombectomy with the Recana device achieved substantial material debulking in patients with chronic, complex ISR, restoring venous patency and potentially improving cephalad flow.

The findings suggest a possible role for mechanical debulking in treating chronic venous obstruction, although additional studies are needed to establish long-term patency and clinical outcomes, advised the investigators in the VIVA summary.